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Abstract
Background: DNA Ligase IV deficiency syndrome is a rare autosomal recessive disorder caused
by hypomorphic mutations in the DNA ligase IV gene (LIG4). The clinical phenotype shows overlap
with a number of other rare syndromes, including Seckel syndrome, Nijmegen breakage syndrome,
and Fanconi anemia. Thus the clinical diagnosis is often delayed and established by exclusion.
Methods: We describe a patient with pre- and postnatal growth retardation and dysmorphic facial
features in whom the diagnoses of Seckel-, Dubowitz-, and Nijmegen breakage syndrome were
variably considered. Cellular radiosensitivity in the absence of clinical manifestations of Ataxia
telangiectasia lead to the diagnosis of DNA ligase IV (LIG4) deficiency syndrome, confirmed by
compound heterozygous mutations in the LIG4  gene. At age 11, after a six year history of
progressive bone marrow failure and increasing transfusion dependency the patient was treated
with matched sibling donor hematopoetic stem cell transplantation (HSCT) using a fludarabine-
based conditioning regimen without irradiation.
Results:  The post-transplantation course was uneventful with rapid engraftment leading to
complete and stable chimerism. Now at age 16, the patient has gained weight and is in good clinical
condition.
Conclusion: HSCT using mild conditioning without irradiation qualifies as treatment of choice in
LIG4-deficient patients who have a matched sibling donor.
Background
DNA Ligase IV deficiency syndrome is a rare autosomal
recessive disorder caused by hypomorphic mutations in
the DNA ligase IV gene (LIG4) [1]. The gene product of the
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LIG4  gene functions in nonhomologous end-joining
(NHEJ), a major repair pathway for DNA double-strand-
breaks in mammalian cells that is activated following
DNA damage, but also during class switch [2] and during
V(DJ) recombination [3]. The clinical phenotype shows
overlap with a number of other rare syndromes, including
Seckel syndrome, Nijmegen breakage syndrome, and Fan-
coni anemia. As a result, the clinical diagnosis is often
delayed and established by exclusion. LIG4-deficient
patients are characterized by microcephaly, growth retar-
dation starting in utero, distinctive facial appearance
("bird-like face"), developmental delay, immunodefi-
ciency, pancytopenia, and pronounced clinical and cellu-
lar radiosensitivity [1,4,5]. According to their
radiosensitive cellular phenotype, LIG4-deficient patients
belong to the group of human radiosensitivity syndromes
which include ataxia telangiectasia (AT), Nijmegen break-
age syndrome (NBS), Rad 50 and Mre 11 deficiency,
thrombocytopenia absent radii syndrome (TAR), Artemis
syndrome, and Cernunnos-XLF syndrome [1,5-8]. LIG4-
deficient patients share features with the genetic instabil-
ity syndrome Fanconi anemia (FA), including growth fail-
ure, bone marrow failure and increased risk of leukemia
[5]. FA patients are successfully treated by hematopoietic
stem cell transplantation (HSCT), preferably from
matched sibling donors [9-13], whereas HSCT has only
rarely been applied in patients with radiosensitivity syn-
dromes [11]. We present the clinical course of a LIG4-defi-
cient patient who is in good condition five years after a
matched sibling donor bone marrow transplantation
(BMT).
Case report
The patient is the second of three children of healthy,
non-consanguineous parents. There was no history of
hereditary disorders in the family. During the 22nd week of
pregnancy sonography suggested microcephaly and severe
growth retardation. Spontaneous uncomplicated delivery
occured at the 35th week. The baby was small for gesta-
tional age (42 cm), and birth weight was 1500 g. Head cir-
cumference was not recorded but described as severely
reduced. Developmental milestones were somewhat
delayed: The girl started walking at the age of 15 months
and began to use single words at the age of 18 months.
Because of her pronounced microcephaly, short stature,
psychomotoric delay and her distinctive facial appearance
("bird-like face"; cf. figure 1) she received the tentative
diagnosis of Seckel syndrome. Her growth velocity
remained below the third percentile (figure 2). Starting at
age five the child developed thrombocytopenia and ane-
mia followed by leukocytopenia (figure 3). A combina-
tion of pancytopenia with features like pre- and postnatal
growth retardation, telecanthus, epicanthal folds, ptosis,
and broadening of the bridge and tip of the nose similar
to our patient had been previously described in two chil-
dren with Dubowitz syndrome [14,15] leading to consid-
eration of this diagnosis. Our patient increasingly suffered
from recurrent infections of the inner ear and respiratory
tract with low immunoglobulin levels, requiring frequent
hospital admissions. Bone marrow histology (at age 8)
showed hypoplastic marrow with cellular dysplasia. This
finding was remarkable since cytopenia in LIG4-deficient
patients has previously been attributed to autoimmunity
rather than to a primary bone marrow defect [16]. Stand-
ard chromosome analysis revealed a female karyotype
(46, XX) without evidence for numerical aberrations.
There were no signs of monosomy 7 or trisomy 8 in bone
marrow preparations, but chromosome breakage studies
of peripheral blood mononuclear cells showed increased
spontaneous breakage. Bleomycin-treatments of 72 h
peripheral blood mononuclear cell cultures yielded
strongly increased breakage rates (cf. table 1), suggesting a
radiosensitive cellular phenotype and the diagnosis of
Nijmegen breakage syndrome. However, no mutations
were found in the nibrin gene. In order to confirm the cel-
lular radiosensivity phenotype, cell cycle analysis using
bivariate BrdU-Hoechst ethidium bromide flow cytome-
try was performed. As illustrated in figure 4, following
irradiation with 1.5 Gy and 72 h in vitro culture, the
patients' mononuclear blood cells proved as radiosensi-
tive as cells from patients with ataxia telangiectasia. Given
a normal serum alpha-fetoprotein (AFP) level and the
absence of clinical features of AT, the diagnosis of AT was
considered unlikely, but diagnostic considerations were
extended to the AT-like syndromes which include the
DNA ligase IV deficiency syndrome. As reported previ-
ously [1] mutation analysis of the LIG4 gene revealed the
mutations G469E (maternal) and R814X (paternal), con-
firming the diagnosis of DNA ligase IV deficiency syn-
drome.
Hematopoietic stem cell transplantation
As illustrated in figure 3, between ages 10 and 11 years the
patient's peripheral blood counts showed continuous
decline requiring substitution with several erythrocyte
concentrates. Bone marrow aspiration revealed strongly
reduced cellularity with very few megakaryocytes confirm-
ing progression of bone marrow hypoplasia such that
there was concern of beginning bone marrow failure (8%
myelocytes, 9% band granulocytes, 9% segmented granu-
locytes, 2% monocytes, 50% erythroblasts, 20% lym-
phocytes). Due to poor cellularity a repeat bone marrow
chromosome study was not attempted. Because of the
patient's continuously decreasing peripheral blood
counts, deteriorating general condition, and the known
risk of LIG4-deficient patients for hematologic malignan-
cies [5,17], the option of a timely BMT was considered.
Her 15-year-old HLA-identical brother was healthy and
carried no ligase IV mutation, making him available as
donor and facilitating the decision in favor of transplanta-Orphanet Journal of Rare Diseases 2007, 2:5 http://www.OJRD.com/content/2/1/5
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tion. On admission to transplant, the patient's white
blood cell (WBC) count was 2.7 × 109/L, platelets were 22
× 109/L, and hemoglobin was 6.6 mmol/L. Immunoglob-
ulin (Ig) levels before transplantation were IgM 0.35 (g/
L), IgG 8.83 (g/L), and IgA 0.74 (g/L). Lymphocyte subsets
were CD3 960, CD4 412, CD8 531, CD19 11, and NK 222
(cells/microlitre). Total lymphocytes (CD45+) were
98.1%, monocytes (CD14/45+) were 1.1%, NK cells
(CD16+56+) were 17.8%, and T cells (CD3+) were
76.8%.
Taking into account the increased cellular radiosensitivity
of our patient, conditioning was ablative yet mild, closely
following the protocol of McCloy et al. [18]. Conditioning
consisted of fludarabine (30 mg/m2/day for 4 days),
cyclophosphamide (10 mg/kg/day for 4 days), and
antithymocyte globulin, ATG (15 mg/kg for 4 days).
Although ATG is not essential in transplants with a fully
matched sibling donor it was given in order to secure both
engraftment and graft versus host disease (GvHD) proph-
ylaxis in the absence of metothrexate. In order to avoid
possible complications of radiosensitivity, the condition-
ing regimen did not include irradiation [18].
The patient received 5.43 × 108/kg nucleated cells of
unmanipulated bone marrow from her HLA-identical
brother. GvHD prophylaxis consisted of cyclosporine A at
3 mg/kg/d from day -1 until day 64 but without addi-
tional methotrexate. On day 5, granulocyte colony- stim-
ulating factor (G-CSF) (5 μg/kg/day) was started and
given until day 22. The patient did not suffer from any
severe side effects and did not even loose her hair. The leu-
kocyte nadir was reached on day -1 with 0.1 × 109/L.
Engraftment was observed as early as day 10 with an abso-
lute neutrophile count (ANC) of > 0.5 × 109/L (74% seg-
mented granulocytes; 10% band granulocytes) and a WBC
of 1.1 × 109/L. Prophylaxis for fungal, viral and bacterial
infections was with acyclovir (30 mg/kg/day from day -2
until day 11), liposomal amphotericin B (1 mg/kg/day
from day 6 until day 10), fluconazol (5 mg/kg/day from
day 12 until day 16), metronidazol (20 mg/kg/day until
day 11), ceftacidim (100 mg/kg/day until day 15), and
penicillin V (50,000 units/kg/day from day 18 until
today). Pneumocystis jiroveci prophylaxis was performed
with cotrimoxazol (5 mg/kg/day; 3 days per week from 1
until 6 months after BMT). Immunoglobulins were given
at a dose of 250 mg/kg/day on days 2, 8, and 19. The
patient received a total of 7 platelet concentrates, the last
on day 13. The girl was discharged on day 22 in good clin-
ical condition with a WBC of 1.2 × 109/L, platelets of 32 ×
109/L, and hemoglobin of 6 mmol/L.
Outcome
Blood chimerism analysis showed 100% donor cells on
day 46. The percentage of donor cells declined to 91% on
day 60 but resurged to 100% following withdrawal of
cyclosporin A. Complete chimerism was established
within 4 months after BMT, remaining stable since that
time. As shown in figure 4, sequential flow cytometric
studies of mitogen response vs. radiosensitivity confirmed
the replacement of radiosensitive patient cells by radiore-
sistant donor cells. Currently at age 16, her immune sys-
tem functions well, with a good immune response
towards all common vaccinations. During the course of
two years after BMT the patient gained considerable
weight. She had always been below the 20th percentile,
Patient at age 12 showing dsymorphic features including  microcephaly (head circumference 43 cm), hypertelorism,  broad nasal bridge, broadened tip of the nose, and thin upper  lip Figure 1
Patient at age 12 showing dsymorphic features including 
microcephaly (head circumference 43 cm), hypertelorism, 
broad nasal bridge, broadened tip of the nose, and thin upper 
lip. A photograph of this patient and the description of her 
mutations have previously been presented in figure 2 of the 
report by O'Driscoll et al. [4]. It should be noted that there 
is a labeling error in the legend of figure 2 in reference [4]: 
The text corresponding to the photograph of our patient is 
marked with (B) but should read (C).Orphanet Journal of Rare Diseases 2007, 2:5 http://www.OJRD.com/content/2/1/5
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Height and weight prior to and after hematopoietic stem cell transplantation (HSCT) Figure 2
Height and weight prior to and after hematopoietic stem cell transplantation (HSCT).Orphanet Journal of Rare Diseases 2007, 2:5 http://www.OJRD.com/content/2/1/5
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whereas now at age 16 she is overweight with 44 kg at 146
cm. Head circumference is 44 cm. Her height is still below
the 3rd percentile, but her general physical condition is
excellent. She is fully active and can lead a normal life
with no restrictions (100% Lansky-Play-performance).
Due to her mild to moderate mental retardation, she cur-
rently attends grade 9 of a special school for mentally
handicapped children, with good success. There are no
skin or genital abnormalities, but puberty is markedly
delayed. There is little pubic hair and breast development,
corresponding to Tanner stages P3 and B3, and the patient
has not yet started menstruating. The hormonal profile is
suggestive of hypergonadotrophic hypogonadism (FSH is
55.5 IU/L, LH 24.2 IU/L, estradiol 73 pmol/L).
Discussion
The clinical history of our patient illustrates the difficulty
of establishing the correct diagnosis in rare growth failure
and dysmorphy syndromes. The key observations that
finally lead to the correct diagnosis were increased cellular
sensitivity towards the radiomimetic bleomcycin (in
terms of chromosome breakage), and increased cellular
sensititvity to ionizing radiation (in terms of G2 phase cell
cycle blockage). After exclusion of the Nijmegen breakage
syndrome by mutation analysis and exclusion of AT on
clinical grounds (supported by normal AFP levels),
sequencing of the LIG4 gene established the diagnosis of
DNA ligase IV deficiency syndrome. Due to the extensive
phenotypic overlap it is conceivable that patients with fea-
tures of the Dubowitz syndrome who in addition suffer
from aplastic anemia [14,15] might eventually turn out to
be affected by the DNA ligase IV deficiency syndrome.
As offspring of a non-consanguinous couple, our patient
was diagnosed as compound heterozygous for an amino
acid change (glycine replaced by glutamate) on the mater-
nal allele and a stop codon mutation on the paternal
allele [1]. Analysis of the impact of the R814X ligase IV
mutation in vivo (hamster cell experiments) revealed an
impaired interaction between ligase IV and XRCC4 (X-ray
repair complementing defective repair in Chinese hamster
cells 4 protein), and an impaired DNA ligase IV adenylate
complex formation with reduced ligation activities [19].
When the G469E ligase IV mutation was analyzed in sev-
eral experiments, a normal interaction with XRCC4 was
observed, but adenylation and ligation activity were
Time course of hematological parameters prior to and after hematopoietic stem cell transplantation (HSCT) Figure 3
Time course of hematological parameters prior to and after hematopoietic stem cell transplantation (HSCT). Broken lines 
denote lack of data.Orphanet Journal of Rare Diseases 2007, 2:5 http://www.OJRD.com/content/2/1/5
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severely reduced, with very little residual ligation activity
[19]. These results suggest that, at least in hamster cells,
both mutations are pathogenic. Since LIG4 null-mutant
mice are embryonic lethal [20] and biallelic null muta-
tions have not been described to date in other LIG4-defi-
cient patients [21,22], viability of the DNA ligase IV
deficiency syndrome appears to require at least one allele
with a hypomorphic mutation. A preserved pattern of
TCR-alpha and beta junctions in the T cells and only mild
to moderate impairment of class switch and V(D)J recom-
bination suggests the presence of residual LIG4 activity in
DNA ligase IV deficient patients [21,22]. The relatively
Table 1
Bleomycin μg/ml 0 0.1 0.25 0.5
negative control 0.06 0.48 0.5 0.98
patient 0.02 1.04 1.28 1.78
positive control 0.06 1.33 1.52 2.4
Chromosome breakage rates (percent breaks per cell) of peripheral blood mononuclear cells exposed to the respective concentrations of the 
radiomimetic bleomycin for four hours. Negative control = blood samples from healthy donors; positive control = blood sample from a proven AT 
patient.
Determination of mitogen response (G0/G1) and radiosensitivity (G2/GF) via bivariate flow cytometry Figure 4
Determination of mitogen response (G0/G1) and radiosensitivity (G2/GF) via bivariate flow cytometry. Circles: radiation 
resistant cases (controls); Triangles: radiosensitive cases (ataxia telangiectasia, AT). Squares: patient blood samples analyzed at 
different time points prior to (1) and after HSCT (2–7). BMT was performed in May 2002. Immunosuppression following BMT 
caused lack of mitogen response (time point 2).Orphanet Journal of Rare Diseases 2007, 2:5 http://www.OJRD.com/content/2/1/5
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mild degree of immunodeficiency observed in our patient
agrees with the notion of residual LIG4 function as pre-
requisite for viability. However, at least some LIG4 defi-
cient patients exhibit a severely compromised immune
system, including complete absence of B lymphocytes and
severely reduced numbers of T cells (SCID phenotype;
[21,22]). This suggests that DNA ligase IV, beyond its well
established role in V(D)J recombination, may have addi-
tional functions in the lymphocytic cell lineage [22].
Together with the XRCC4 protein, DNA ligase IV func-
tions in non-homologous end joining (NHEJ), the major
repair process of double strand breaks in mammalian cells
[23]. DNA repair via NHEJ takes place during G0, G1, and
early S phase of the cell cycle and requires Ku (a Ku70/
Ku80 heterodimer), DNA-dependent protein kinase cata-
lytic subunit (DNA-PKcs), and the XRCC4/LIG4 complex
proteins [24-26]. It is assumed that Ku or Rag binds to the
DSB first, then recruits DNA-PKcs and Artemis, a nuclease
that trims DNA ends allowing the LIG4/XRCC4 complex
to perform religation [24-26]. In addition, NHEJ is essen-
tial for the generation of T cell receptor and immunoglob-
ulin diversity. Impairment of class switch and of V(D)J
recombination therefore explain the immunodeficiency
and proneness to multiple myeloma and lymphoma
observed in LIG4-deficient patients [17,26]. It does not,
however, explain the propensity to bone marrow failure.
In analogy to the bone marrow failure syndromes Fanconi
anemia and Dyskeratosis congenita which are character-
ized by instability of chromosomes or telomeres [27,28],
genetic instability due to LIG4 deficiency might explain
increased radiosensitivity and bone marrow failure in
LIG4-deficient patients.
It has previously been shown in mice that ligase IV is
essential for neuronal cell development [29]: Disruption
of NHEJ due to ligase IV deficiency leads to impaired pre-
natal differentiation of neuronal cells. This may explain
the mild to moderate mental retardation observed in our
patient.
Like in Fanconi anemia and a single previously reported
patient with the Nijmegen breakage syndrome, our
patient illustrates that HSCT can be an effective treatment
of LIG4-deficiency. Since our patient had a matched sib-
ling donor available, a six-year history of progressive bone
marrow failure requiring increasing rates of blood product
substitution, and since she showed signs of developing
myelodysplastic syndrome (MDS), HSCT was the most
promising therapeutic option. It should be pointed out,
however, that HSCT in our LIG4-patient was prompted by
bone marrow hypo-and dysplasia rather than by a SCID
phenotype as in other patients with LIG4 syndrome
[22,16].
To our knowledge, this is the first detailed description of
a modified conditioning regimen for BMT and of the clin-
ical course after transplantation in a Ligase IV deficiency
patient. In other publications [1,4] BMT is briefly men-
tioned, but neither the procedure nor the outcome have
been described in detail in any of the previous patients.
Due to our patient's cellular radiosensitivity, she most
likely would not have tolerated a conditioning regimen
using total body irradiation and high dose cyclophospha-
mide. In addition, such aggressive conditioning would
have increased her risk of secondary malignancies [30].
Our protocol therefore used a mild conditioning regimen
without any irradiation, a reduced dose of cyclophospha-
mide, and no methotrexate for GvHD prophylaxis. This
reduced toxicity lead to rapid engraftment without severe
side effects, complete and stable chimerism at 4 months,
and good clinical condition at four years after transplant.
Conclusion
HSCT using mild conditioning without irradiation quali-
fies as treatment of choice in LIG4-deficient patients who
have a matched sibling donor. In addition, the develop-
ment of bone marrow failure in our patient suggests that
at least some forms of Ligase IV deficiency belong to the
inherited bone marrow failure syndromes.
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